ORIGINAL RESEARCH
Accepted on 28 Jul 2025
Predictors of Recurrence After Conversion therapy in Unresectable Hepatocellular Carcinoma Treated with HAIC, Bevacizumab, and Sintilimab
doi 10.3389/fimmu.2025.1644570
- 172 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- New Approaches to Neoadjuvant Therapy and Translational Resection in Hepatobiliary Malignancies, Volume II
New Approaches to Neoadjuvant Therapy and Translational Resection in Hepatobiliary Malignancies, Volume II
1,292
Total downloads
6,024
Total views and downloads
Articles
CASE REPORT
Published on 04 Jun 2025
Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report
doi 10.3389/fimmu.2025.1529016
- 1,174 views
ORIGINAL RESEARCH
Published on 02 Jun 2025
Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging
doi 10.3389/fimmu.2025.1596864
- 1,242 views
ORIGINAL RESEARCH
Published on 26 Nov 2024
FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study
doi 10.3389/fimmu.2024.1471017
- 2,020 views
- 6 citations
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore